What is Hunan Er-Kang Pharmaceutical Co Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Hunan Er-Kang Pharmaceutical Co Enterprise Value Chart
Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Er-Kang Pharmaceutical Co's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Enterprise Value falls into.
Hunan Er-Kang Pharmaceutical Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Hunan Er-Kang Pharmaceutical Co's EV-to-EBIT for today is
Hunan Er-Kang Pharmaceutical Co's current Enterprise Value is ¥5,202 Mil.
Hunan Er-Kang Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-212 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Hunan Er-Kang Pharmaceutical Co's EV-to-EBITDA for today is:
Hunan Er-Kang Pharmaceutical Co's current Enterprise Value is ¥5,202 Mil.
Hunan Er-Kang Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-212 Mil.
Hunan Er-Kang Pharmaceutical Co's current Enterprise Value is ¥5,202 Mil.
Hunan Er-Kang Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,512 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Er-Kang Pharmaceutical Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300267 has been successfully added to your 